The influenza replication blocking inhibitor LASAG does not sensitize human epithelial cells for bacterial infections

Severe influenza virus (IV) infections still represent a major challenge to public health. To combat IV infections, vaccines and antiviral compounds are available. However, vaccine efficacies vary with very limited to no protection against newly emerging zoonotic IV introductions. In addition, the d...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilden, Janine J., van Krüchten, Andre, Gieselmann, Lutz, Hrincius, Eike R., Deinhardt-Emmer, Stefanie, Haupt, Karoline F., Preugschas, Hannah F., Niemann, Silke, Ludwig, Stephan, Ehrhardt, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228112/
https://www.ncbi.nlm.nih.gov/pubmed/32413095
http://dx.doi.org/10.1371/journal.pone.0233052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228112/
https://www.ncbi.nlm.nih.gov/pubmed/32413095
http://dx.doi.org/10.1371/journal.pone.0233052

Ejemplares similares